Factor IX

"Factor IX" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Storage-stable blood coagulation factor acting in the intrinsic pathway. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease).

Descriptor ID

D005164

MeSH Number(s)

D12.776.124.125.375

D23.119.375

Concept/Terms

Factor IX

Below are MeSH descriptors whose meaning is more general than "Factor IX".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Blood Coagulation Factors [D12.776.124.125]
Factor IX [D12.776.124.125.375]
Biological Factors [D23]
Blood Coagulation Factors [D23.119]
Factor IX [D23.119.375]

Below are MeSH descriptors whose meaning is more specific than "Factor IX".

Factor IX
Factor IXa

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Factor IX" by people in Harvard Catalyst Profiles by year, and whether "Factor IX" was a major or minor topic of these publication.

Bar chart showing 52 publications over 27 distinct years, with a maximum of 6 publications in 2004

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	1	0	1
1995	0	1	1
1996	1	1	2
1997	1	0	1
1998	3	1	4
2000	0	2	2
2001	0	2	2
2002	3	0	3
2004	3	3	6
2006	0	1	1
2007	1	1	2
2009	2	0	2
2010	0	1	1
2011	1	1	2
2012	0	1	1
2013	2	0	2
2014	1	0	1
2015	1	1	2
2016	1	1	2
2017	0	1	1
2018	0	3	3
2019	2	1	3
2020	1	1	2
2021	2	0	2
2022	0	1	1
2023	1	0	1
2024	0	1	1

Below are the most recent publications written about "Factor IX" by people in Profiles.

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial. Lancet Haematol. 2024 Apr; 11(4):e265-e275.

View in: PubMed
INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma. Blood Adv. 2023 05 23; 7(10):2206-2213.

View in: PubMed
Hemophilia A/B. Hematol Oncol Clin North Am. 2022 08; 36(4):797-812.

View in: PubMed
Inherent hepatocytic heterogeneity determines expression and retention of edited F9 alleles post-AAV/CRISPR infusion. Proc Natl Acad Sci U S A. 2021 10 19; 118(42).

View in: PubMed
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021 02 11; 137(6):763-774.

View in: PubMed
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2021 Jan; 27(1):49-59.

View in: PubMed
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. Haemophilia. 2020 May; 26(3):e128-e129.

View in: PubMed
Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates. Blood Adv. 2019 09 10; 3(17):2632-2641.

View in: PubMed
Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019 Jul; 25(4):668-675.

View in: PubMed
Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B. Haemophilia. 2019 03; 25(2):e126-e129.

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Haemophilia
Blood
Thromb Haemost
Biochemistry
Proc Natl Acad Sci U S A
N Engl J Med
J Thromb Haemost
Haematologica
J Clin Invest
Br J Haematol